NCT00626613 is a Phase 4 clinical trial of Risperdal,reminyl in Dementia, sponsored by Jinan Mental Hospital.

Who is sponsoring NCT00626613?

NCT00626613 is sponsored by Jinan Mental Hospital.

What drugs are being tested in NCT00626613?

Interventions in NCT00626613: Risperdal,reminyl.

What condition does NCT00626613 study?

NCT00626613 studies Dementia, Alzheimer's Disease.

Is NCT00626613 still recruiting?

NCT00626613 is currently status unknown. Last updated 29 February 2008.

Last reviewed 2008-02-29 · How we verify

NCT00626613

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN)

Status unknown Phase 4 Last updated 29 February 2008

What this trial tests

Phase 4 trial testing Risperdal,reminyl in Dementia. Status unknown.

Quick facts

Lead sponsor	Jinan Mental Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	double
Sites	1 location across Taiwan

Drugs / interventions tested

Risperdal,reminyl — full drug profile →

Conditions studied

Dementia — all drugs for Dementia →
Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Jinan Mental Hospital

Who can join

60 and older, any sex, with Dementia or Alzheimer's Disease. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Neoropsychiatric Inventory (NPI)Cognitive Abilities Screening Instrument (CASI) SF-36abnormal involuntary movement scale (AIMS), Barnes akathisia rating scale (BARS), and Simpson angus scale (SAS)
Time frame: one year

Sponsor's own description

To evaluate the relationship between Risperidone Treatment, Treatment Discontinuation Rate, and Quality of Life of patients with Alzheimer's Disease and BPSD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials.
Liu KY, Borissova A, Mahmood J, Elliott T, et al · · 2021 · cited 11× · PMID 33816763 · DOI 10.1002/trc2.12157

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT06088810 — The Impact of Music Intervention on Sleep · NA · recruiting
NCT07482800 — Dementia in Fiction and Clinical Narratives · recruiting
NCT07392944 — Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Home · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00626613 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jinan Mental Hospital
Last refreshed: 29 February 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00626613.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing